Literature DB >> 16873060

A CK2-dependent mechanism for degradation of the PML tumor suppressor.

Pier Paolo Scaglioni1, Thomas M Yung, Lu Fan Cai, Hediye Erdjument-Bromage, Andrew J Kaufman, Bhuvanesh Singh, Julie Teruya-Feldstein, Paul Tempst, Pier Paolo Pandolfi.   

Abstract

The PML tumor suppressor controls key pathways for growth suppression, induction of apoptosis, and cellular senescence. PML loss occurs frequently in human tumors through unknown posttranslational mechanisms. Casein kinase 2 (CK2) is oncogenic and frequently upregulated in human tumors. Here we show that CK2 regulates PML protein levels by promoting its ubiquitin-mediated degradation dependent on direct phosphorylation at Ser517. Consequently, PML mutants that are resistant to CK2 phosphorylation display increased tumor-suppressive functions. In a faithful mouse model of lung cancer, we demonstrate that Pml inactivation leads to increased tumorigenesis. Furthermore, CK2 pharmacological inhibition enhances the PML tumor-suppressive property in vivo. Importantly, we found an inverse correlation between CK2 kinase activity and PML protein levels in human lung cancer-derived cell lines and primary specimens. These data identify a key posttranslational mechanism that controls PML protein levels and provide therapeutic means toward PML restoration through CK2 inhibition.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16873060     DOI: 10.1016/j.cell.2006.05.041

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  130 in total

1.  The SUMO E3-ligase PIAS1 regulates the tumor suppressor PML and its oncogenic counterpart PML-RARA.

Authors:  Andrea Rabellino; Brandon Carter; Georgia Konstantinidou; Shwu-Yuan Wu; Alessandro Rimessi; Lauren A Byers; John V Heymach; Luc Girard; Cheng-Ming Chiang; Julie Teruya-Feldstein; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2012-03-09       Impact factor: 12.701

2.  Another road leads to HIF-1 activation: implications for prostate cancer progression.

Authors:  Yao Dai; Kyungmi Bae; Dietmar W Siemann
Journal:  Asian J Androl       Date:  2011-11-21       Impact factor: 3.285

3.  Functions of the Epstein-Barr virus EBNA1 protein in viral reactivation and lytic infection.

Authors:  Nirojini Sivachandran; Xueqi Wang; Lori Frappier
Journal:  J Virol       Date:  2012-04-04       Impact factor: 5.103

Review 4.  PML nuclear bodies.

Authors:  Valérie Lallemand-Breitenbach; Hugues de Thé
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-04-21       Impact factor: 10.005

5.  The tumor suppressor Pml regulates cell fate in the developing neocortex.

Authors:  Tarik Regad; Cristian Bellodi; Pierluigi Nicotera; Paolo Salomoni
Journal:  Nat Neurosci       Date:  2009-01-11       Impact factor: 24.884

6.  Identification of a non-covalent ternary complex formed by PIAS1, SUMO1, and UBC9 proteins involved in transcriptional regulation.

Authors:  Xavier H Mascle; Mathieu Lussier-Price; Laurent Cappadocia; Patricia Estephan; Luca Raiola; James G Omichinski; Muriel Aubry
Journal:  J Biol Chem       Date:  2013-10-30       Impact factor: 5.157

7.  Identification of a novel protein interaction motif in the regulatory subunit of casein kinase 2.

Authors:  Jennifer Yinuo Cao; Kathy Shire; Cameron Landry; Gerald D Gish; Tony Pawson; Lori Frappier
Journal:  Mol Cell Biol       Date:  2013-11-11       Impact factor: 4.272

Review 8.  Nuclear microenvironment in cancer diagnosis and treatment.

Authors:  Rossanna C Pezo; Robert H Singer
Journal:  J Cell Biochem       Date:  2008-08-15       Impact factor: 4.429

9.  CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.

Authors:  P P Scaglioni; T M Yung; S Choi; S C Choi; C Baldini; G Konstantinidou; P P Pandolfi
Journal:  Mol Cell Biochem       Date:  2008-06-20       Impact factor: 3.396

10.  Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations.

Authors:  Georgia Konstantinidou; Erik A Bey; Andrea Rabellino; Katja Schuster; Michael S Maira; Adi F Gazdar; Augusto Amici; David A Boothman; Pier Paolo Scaglioni
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.